Loading...
NPI 1568574465 · Las Vegas, NV · End-Stage Renal Disease (ESRD) Treatment Clinic/Center
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Bio-medical Applications Of Nevada, LLC is a end-stage renal disease (esrd) treatment clinic/center provider located in Las Vegas, Nevada. This profile covers 0 Medicare and 59 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Bio-medical Applications Of Nevada, LLC |
| Address | 2545 S Bruce St Ste 100 |
| City | Las Vegas |
| State | NV |
| ZIP | 89169 |
| Taxonomy | End-Stage Renal Disease (ESRD) Treatment Clinic/Center |
| NPI Enumerated | August 31, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $14M |
| Medicare | $0 |
BIO-MEDICAL APPLICATIONS OF NEVADA, LLC is an End-Stage Renal Disease (ESRD) Treatment Clinic/Center located in LAS VEGAS, NV with an NPI enumerated on 2006-08-31 (~20 years ago), indicating long-standing presence in the market. Its taxonomy and long tenure are consistent with an established dialysis operator serving Medicaid patients in-state.
This provider has no Medicare billing on file and all reported lifetime revenue is from Medicaid, with total Medicaid revenue of $14M; operationally it functions as effectively single-payer (Medicaid) in the available claims data. Analysts should treat Medicaid as the primary commercial exposure for revenue risk and reimbursement dynamics.
Revenue is highly concentrated in a small set of procedure codes: the top 3 Medicaid codes account for 100.0% of the provider's total Medicaid revenue, with code 90999 alone representing $13.8M or 99.0% of Medicaid revenue. The other two top codes are J0887 ($133.8K, 1.0%) and 90732 ($414, 0.0%), confirming that dialysis services drive virtually all paid Medicaid dollars.
The code mix and descriptions point to an operation centered on dialysis services and routine in-center care: 90999 (unspecified dialysis services) is the dominant revenue driver, while numerous high-volume laboratory and supply codes (for example, 85018 with 39.3K claims and A4657 with 89.6K claims) align with typical dialysis patient monitoring and supplies. This pattern is consistent with a dialysis clinic model that bills per-treatment dialysis codes while performing frequent labs and using large volumes of consumables.
Competitively, the provider is a statewide leader for its primary dialysis and related injectable codes: 90999 ranks #1 of 53 providers in-state (100th percentile; extreme outlier) and J0887 ranks #1 of 40 providers in-state (100th percentile; extreme outlier). Those rank and percentile positions indicate the provider is an unusually large volume performer in Nevada for dialysis services and ESA administration compared with in-state peers.
A number of commonly used lab and drug administration codes show very high claim counts but report $0 avg paid/claim (for example, 82310 13.3K claims $0, 83550 13.1K claims $0, J1756 38.9K claims $0). This billing pattern suggests many diagnostics, infusions, and supplies are either bundled into the primary dialysis reimbursement or are not separately reimbursed by Medicaid, concentrating paid revenue into the dialysis procedure codes.
Clinical service signals include substantial use of erythropoiesis-stimulating agent billing (J0887 with 16.7K claims, $8 avg paid/claim) and in-center preventive services (90732 with 207 claims, $2 avg paid/claim). These entries support an operational model that delivers anemia management and routine vaccinations alongside dialysis treatments.
Despite the extremely concentrated Medicaid revenue base, the very large claim volumes across multiple supporting codes (examples: A4657 89.6K claims; 85018 39.3K claims; 84520 26.1K claims) imply high patient throughput and consistent recurring utilization typical of a high-volume dialysis center; however, nearly all paid dollars flow through a single dominant code (90999).
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
59 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 90999 | Use 90999 to report dialysis services or procedures that do not have a specific code. | 184,440 | $80 | $13.8M |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 16,720 | $10 | $133.8K |
| 90732 | The provider intramuscularly or subcutaneously injects pneumococcal polysaccharide vaccine in an individual two years or older. This vaccine provides protection against meningitis and pneumonia that… | 210 | $1 | $410 |
| 0001A | N/A | 120 | $0 | $0 |
| 0002A | N/A | 110 | $0 | $0 |
| 0064A | N/A | 90 | $0 | $0 |
| 80051 | The lab analyst performs an electrolyte panel; this panel must include measurement of carbon dioxide, chloride, potassium, and sodium. | 7,050 | $0 | $0 |
| 80069 | The lab analyst performs a renal function panel test in which he measures the blood level of certain chemicals the descriptor lists to evaluate how well the kidney is functioning. | 5,770 | $0 | $0 |
| 82040 | The lab analyst performs a quantitative measurement on a serum, plasma, or whole blood specimen for albumin. | 7,550 | $0 | $0 |
| 82108 | The lab analyst performs a quantitative measurement of the element aluminum. Most commonly the source is serum or urine. This quantitation is important in patients on kidney dialysis or medications… | 1,270 | $0 | $0 |
Showing 1–10 of 59
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
59 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 90999 | Use 90999 to report dialysis services or procedures that do not have a specific code. | 1 | 50 | 43,690 | $60 | $3.4M |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 30 | 160 | 1,190 | $1 | $39.8K |
| 86803 | Qualitative or Semiquantitative Immunoassays; Hepatitis C antibody | 13 | 30 | 100 | $1 | $18.1K |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 1 | 40 | 1,480 | $10 | $16.3K |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 86 | 130 | 330 | $1 | $15.6K |
| 82607 | The lab analyst performs a test to measure the amount of vitamin B12 in a patient specimen, typically in patient blood. | 30 | 50 | 300 | $1 | $14.2K |
| 83735 | The lab analyst performs a test to measure the amount of magnesium in a patient specimen. | 24 | 90 | 1,660 | $1 | $10.3K |
| 83970 | Parathyroid hormone test measures the level of PTH in the blood. This test is done to ascertain the level of calcium and evaluate the parathyroid function. | 2 | 50 | 1,630 | $1 | $10K |
| 82746 | The lab analyst measures the folic acid level in serum to determine if there is a deficiency. Folic acid deficiency is attributed to many conditions such as malabsorption, Crohn’s disease, celiac… | 8 | 50 | 180 | $1 | $9.2K |
| 87340 | The lab analyst performs a test to detect hepatitis B surface antigen, also called HBsAg, using an immunoassay technique, such as EIA. | 4 | 30 | 980 | $1 | $7.7K |
Showing 1–10 of 59
Other providers in the same ZIP code as Bio-medical Applications Of Nevada, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.